In-process specifications are not derived from previous acceptable process average and process variability estimates where possible.
Inspection Record
Packagina On Demand, Inc. — FDA 483 Findings
Inspectors Kham Phommachanh · Pearl C Ozuruigbo · Wenzheng ZhangThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Drug product reserve samples are not stored in the same immediate container-closure system as the marketed product and an immediate container-closure system that has essentially the same characteristics as the marketed product.
The persons performing and double-checking the cleaning and maintenance are not dating and signing or initialing the equipment cleaning and use log.
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
The number of containers to be sampled and amount of material taken from each container is not based upon appropriate criteria.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- BSP Pharmaceuticals S.p.A.2022-03-31 · US FDASimilar to finding 4 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
- Phoenix Innovative Healthcare Manufactures Private Limited2024-09-27 · US FDASimilar to finding 4 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations…
- Hybrid Pharma LLC2026-08-27 · US FDASimilar to finding 4 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use…
- Emcure Pharmaceuticals Limited2026-05-15 · US FDASimilar to finding 4 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
- Novel Laboratories, Inc. d.b.a Lupin Somerset2026-04-17 · US FDASimilar to finding 5 The number of containers to be sampled and amount of material taken from each container is not based upon appropriate criteria.
A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.